{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T03:21:28Z","timestamp":1771125688223,"version":"3.50.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Extensively drug-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (XDR-PA) is a growing concern due to its increasing incidence, limited therapeutic options, limited data on the optimal treatment, and high mortality rates. The study aimed to characterize the population, the outcome and the microbiological characteristics of XDR-PA identified in a Portuguese university hospital center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All XDR-PA isolates between January 2019 and December 2021 were identified. XDR-PA was defined as resistance to piperacillin-tazobactam, third and fourth generation cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. A retrospective analysis of the medical records was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred seventy-eight individual episodes among 130 patients with XDR-PA detection were identified. The most common sources of infection were respiratory (32%) and urinary tracts (30%), although skin and soft tissue infections (18%) and primary bacteremia (14%) were also prevalent. Colonization was admitted in 64 cases. Several patients had risk factors for complicated infections, most notably immunosuppression, structural lung abnormalities, major surgery, hemodialysis or foreign intravascular or urinary devices. XDR-PA identification was more frequent in male patients with an average age of 64.3 \u00b1 17.5 years. One non-susceptibility to colistin was reported. Only 12.4% were susceptible to aztreonam. Ceftazidime-avibactam (CZA) was susceptible in 71.5% of the tested isolates. Ceftolozane-tazobactam (C\/T) was susceptible in 77.5% of the tested isolates. Antibiotic regimens with XDR-PA coverage were reserved for patients with declared infection, except to cystic fibrosis. The most frequently administered antibiotics were colistin (41 cases), CZA (39 cases), and C\/T (16 cases). When combination therapy was used, CZA plus colistin was preferred. The global mortality rate among infected patients was 35.1%, significantly higher in those with hematologic malignancy (50.0%, <jats:italic>p<\/jats:italic> &amp;lt; 0.05), followed by the ones with bacteremia (44.4%, <jats:italic>p<\/jats:italic> &amp;lt; 0.05) and those medicated with colistin (39.0%, <jats:italic>p<\/jats:italic> &amp;lt; 0.05), especially the ones with respiratory infections (60.0%). Among patients treated with CZA or C\/T, the mortality rate seemed to be lower.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>XDR-PA infections can be severe and difficult to treat, with a high mortality rate. Even though colistin seems to be a viable option, it is likely less safe and efficient than CZA and C\/T. To the best of the authors\u2019 knowledge, this is the first description of the clinical infection characteristics and treatment of XDR-PA in Portugal.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2024.1347521","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T03:41:44Z","timestamp":1707795704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime\/avibactam and ceftolozane\/tazobactam in a tertiary care university hospital center in Portugal \u2013 A cross-sectional and retrospective observational study"],"prefix":"10.3389","volume":"15","author":[{"given":"Diogo","family":"Mendes Pedro","sequence":"first","affiliation":[]},{"given":"S\u00e9rgio Eduardo","family":"Paulo","sequence":"additional","affiliation":[]},{"given":"Carla Mimoso","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Ana Bruschy","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Melo Cristino","sequence":"additional","affiliation":[]},{"given":"\u00c1lvaro Ayres","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"C\u00e1tia","family":"Caneiras","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1135614","article-title":"Editorial: emerging multidrug-resistant bacterial pathogens \u201csuperbugs\u201d: a rising public health threat.","volume":"14","author":"Algammal","year":"2023","journal-title":"Front. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/QCO.0000000000000505","article-title":"Rational approach in the management of Pseudomonas aeruginosa infections.","volume":"31","author":"Bassetti","year":"","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections.","volume":"7","author":"Bassetti","year":"","journal-title":"Drugs Context"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.975616","article-title":"Editorial: current perspectives on Pseudomonas aeruginosa: epidemiology, virulence and contemporary strategies to combat multidrug-resistant (MDR) pathogens.","volume":"13","author":"Behzadi","year":"","journal-title":"Front. Microbiol."},{"key":"B5","article-title":"Relationship between biofilm-formation, phenotypic virulence factors and antibiotic resistance in environmental Pseudomonas aeruginosa.","volume":"11","author":"Behzadi","year":"","journal-title":"Pathogens"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1007\/s11033-020-05651-9","article-title":"Metallo-\u00df-lactamases: a review.","volume":"47","author":"Behzadi","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1099\/jmm.0.073262-0","article-title":"Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.","volume":"63","author":"Dantas","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1590\/0037-8682-0506-2017","article-title":"Mortality in patients with multidrug-resistant Pseudomonas aeruginosa infections: a meta-analysis.","volume":"51","author":"de Matos","year":"2018","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain.","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.","volume":"74","author":"Del Barrio-Tofin\u00f5","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01541-19","article-title":"Susceptibility of Pseudomonas aeruginosa recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics.","volume":"64","author":"Ekkelenkamp","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1574-6941.12301","article-title":"Faecal carriage of Pseudomonas aeruginosa in healthy humans: antimicrobial susceptibility and global genetic lineages.","volume":"89","author":"Estepa","year":"2014","journal-title":"FEMS Microbiol. Ecol."},{"key":"B14","doi-asserted-by":"publisher","year":"2023","journal-title":"Antimicrobial resistance surveillance in Europe 2023\u20132021 data.","DOI":"10.2900\/63495"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1093\/cid\/ciy801","article-title":"Rapid molecular diagnostics to inform empiric use of ceftazidime\/avibactam and ceftolozane\/tazobactam against Pseudomonas aeruginosa: PRIMERS IV.","volume":"68","author":"Evans","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/AAC.00224-06","article-title":"Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa Bacteremia.","volume":"50","author":"Falagas","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/jac\/dku025","article-title":"Ceftazidime\/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).","volume":"69","author":"Flamm","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106022","article-title":"Assessment of polymyxin B\u2013doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.","volume":"56","author":"Gaurav","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/life11060474","article-title":"Ceftolozane\/tazobactam for resistant drugs Pseudomonas aeruginosa respiratory infections: a systematic literature review of the real-world evidence.","volume":"11","author":"Giaccari","year":"2021","journal-title":"Life"},{"key":"B20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jac\/dkx453","article-title":"Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane\/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.","volume":"73","author":"Giani","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1128\/AAC.03419-14","article-title":"Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients.","volume":"58","author":"G\u00f3mez-Zorrilla","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/jac\/dkaa430","article-title":"Distinct epidemiology and resistance mechanisms affecting ceftolozane\/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.","volume":"76","author":"Hern\u00e1ndez-Garc\u00eda","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/femsle\/fnab099","article-title":"In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study).","volume":"368","author":"Hern\u00e1ndez-Garc\u00eda","year":"","journal-title":"FEMS Microbiol. Lett."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020388","article-title":"Presence of chromosomal crpp-like genes is not always associated with ciprofloxacin resistance in Pseudomonas aeruginosa clinical isolates recovered in ICU patients from Portugal and Spain.","volume":"9","author":"Hern\u00e1ndez-Garc\u00eda","year":"","journal-title":"Microorganisms"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections.","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010275","article-title":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia.","volume":"9","author":"Jean","year":"2020","journal-title":"J. Clin. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040761","article-title":"Novel antimicrobial agents for gram-negative pathogens.","volume":"12","author":"Karvouniaris","year":"2023","journal-title":"Antibiotics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/1534734620958364","article-title":"A retrospective analysis of microbiologic profile of foot infections in patients with diabetic end-stage renal disease.","volume":"20","author":"K\u00f6rpinar","year":"2021","journal-title":"Int. J. Low. Extrem. Wounds"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178178","article-title":"Pseudomonas aeruginosa urinary tract infections in hospitalized patients: mortality and prognostic factors.","volume":"12","author":"Lamas Ferreiro","year":"2017","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.","volume":"73","author":"Livermore","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40121-021-00570-z","article-title":"Aminoglycoside or polymyxin monotherapy for treating complicated urinary tract infections caused by extensively drug-resistant Pseudomonas aeruginosa: a propensity score-adjusted and matched cohort study.","volume":"11","author":"L\u00f3pez Montesinos","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5588\/pha.21.0048","article-title":"Pseudomonas aeruginosa in Nepali hospitals: poor outcomes amid 10 years of increasing antimicrobial resistance.","volume":"11","author":"Mahto","year":"2021","journal-title":"Public Health Action"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"iv32","DOI":"10.1093\/jac\/dkz285","article-title":"Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.","volume":"74","author":"McCracken","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020167","article-title":"First description of ceftazidime\/avibactam resistance in a ST13 KPC-70-producing Klebsiella pneumoniae strain from Portugal.","volume":"11","author":"Mendes","year":"2022","journal-title":"Antibiotics"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107013","article-title":"Genomic characterisation of a novel KPC-98-producing clinical Klebsiella pneumoniae strain conferring resistance to ceftazidime\/avibactam.","volume":"62","author":"Mendes","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B39","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","article-title":"Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.","volume":"13","author":"Mesaros","year":"2007","journal-title":"Clin. Microbiol. Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1128\/AAC.03074-15","article-title":"Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study.","volume":"60","author":"Miller","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-020-05224-w","article-title":"Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran.","volume":"13","author":"Mirzaei","year":"2020","journal-title":"BMC Res. Notes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ijantimicag.2016.10.013","article-title":"Susceptibility to cephalosporin combinations and aztreonam\/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.","volume":"49","author":"Mischnik","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.22038\/ijbms.2021.57293.12748","article-title":"Epidemiology and high incidence of metallo-\u03b2-lactamase and AmpC-\u03b2-lactamases in nosocomial Pseudomonas aeruginosa.","volume":"24","author":"Muddassir","year":"2021","journal-title":"Iran. J. Basic Med. Sci."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193431","article-title":"Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.","volume":"13","author":"Palavutitotai","year":"2018","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10096-012-1758-8","article-title":"Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality.","volume":"32","author":"Pe\u00f1a","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1007\/s10096-012-1629-3","article-title":"Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.","volume":"31","author":"Pe\u00f1a","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/mdr.2014.0137","article-title":"Multidrug and extensive drug resistance in Pseudomonas aeruginosa clinical isolates from a Portuguese central hospital: 10-year survey.","volume":"21","author":"Pereira","year":"2015","journal-title":"Microb. Drug Resist."},{"key":"B48","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/mdr.2013.0029","article-title":"Prevalence and molecular epidemiology of imipenem-resistant Pseudomonas aeruginosa carrying metallo-beta-lactamases from two central hospitals in Portugal.","volume":"19","author":"Pereira","year":"2013","journal-title":"Microb. Drug Resist."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/jac\/dkz030","article-title":"High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.","volume":"74","author":"P\u00e9rez","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.37201\/req\/006.2021","article-title":"Utilization study in real clinical practice of ceftolozane\/tazobactam vs aminoglycosides and\/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa.","volume":"34","author":"Pinilla-Rello","year":"2021","journal-title":"Rev. Esp. Quimioter."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-561","article-title":"A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study.","volume":"13","author":"Quartin","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijantimicag.2018.03.018","article-title":"Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm.","volume":"52","author":"Recio","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1099\/jmmcr.0.005154","article-title":"Extensively drug-resistant (XDR) Pseudomonas aeruginosa identified in Lima, Peru co-expressing a VIM-2 metallo-\u03b2-lactamase, OXA-1 \u03b2-lactamase and GES-1 extended-spectrum \u03b2-lactamase.","volume":"5","author":"R\u00edos","year":"2018","journal-title":"JMM Case Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00408-019-00285-6","article-title":"Development of chronic Pseudomonas aeruginosa-positive respiratory cultures in children with tracheostomy.","volume":"197","author":"Russell","year":"2019","journal-title":"Lung"},{"key":"B55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2478\/v10042-008-0020-9","article-title":"Metallo-\u03b2-lactamases of Pseudomonas aeruginosa\u2013A novel mechanism resistance to \u03b2-lactam antibiotics.","volume":"46","author":"Sacha","year":"2008","journal-title":"Folia Histochem. Cytobiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","article-title":"Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from united states medical centers stratified by infection type: results from the international network for optimal resistance monitoring (INFORM) surveillance program.","volume":"92","author":"Sader","year":"","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program.","volume":"62","author":"Sader","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_239_16","article-title":"Distribution of the strains of multidrug-resistant, extensively drug-resistant, and pandrug-resistant Pseudomonas aeruginosa isolates from burn patients.","volume":"6","author":"Safaei","year":"2017","journal-title":"Adv. Biomed. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s15010-014-0635-z","article-title":"Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.","volume":"42","author":"Samonis","year":"2014","journal-title":"Infection"},{"key":"B61","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1574-6976.2011.00269.x","article-title":"Pseudomonas genomes: diverse and adaptable.","volume":"35","author":"Silby","year":"2011","journal-title":"FEMS Microbiol. Rev."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.47.19045-en","article-title":"Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe.","volume":"13","author":"Souli","year":"2008","journal-title":"Euro Surveill."},{"key":"B63","author":"Suetens","year":"2023","journal-title":"Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals: 2016-2017."},{"key":"B64","author":"Tamma","year":"2022","journal-title":"Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023; Version 3.0"},{"key":"B65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.diagmicrobio.2017.05.003","article-title":"Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.","volume":"88","author":"Tofas","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/0377-4929.41683","article-title":"Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients.","volume":"51","author":"Varaiya","year":"2008","journal-title":"Indian J. Pathol. Microbiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1128\/AAC.00900-09","article-title":"Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum \u03b2-lactamases GES-1 and GES-5 in Spain.","volume":"53","author":"Viedma","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.diagmicrobio.2016.10.003","article-title":"Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: results of the Canadian Ward surveillance study (CANWARD), 2008\u20132015.","volume":"87","author":"Walkty","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajic.2015.01.028","article-title":"Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010.","volume":"43","author":"Werth","year":"2015","journal-title":"Am. J. Infect. Control"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0650-9","article-title":"Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.","volume":"14","author":"Willmann","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.741940","article-title":"Cefiderocol: an overview of its in-vitro and in-vivo activity and underlying resistant mechanisms.","volume":"8","author":"Yao","year":"2021","journal-title":"Front. Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1347521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T03:41:49Z","timestamp":1707795709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1347521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":71,"alternative-id":["10.3389\/fmicb.2024.1347521"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1347521","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"article-number":"1347521"}}